Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0174-1213 A · 1 trial · 2 indications
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| Part A: NNC0174-1213 (SD1-SD5) | EXPERIMENTAL | Part A: Single ascending dose (SAD) of NNC0174-1213 will be administered in cohorts 1-5. |
| Part A: Cagrilintide (SDA and SDB) | EXPERIMENTAL | Part A: Single ascending dose (SAD): Cagrilintide SDA will be administered in cohort 1 and 2. Cagrilintide SDB will be administered in cohort 3 and 4. |
| Part A: Placebo | EXPERIMENTAL | Part A: Single ascending dose (SAD) of placebo will be administered to cohorts 1-5. |
| Part B: NNC0174-1213 (MD1-MD5) | EXPERIMENTAL | Part B: Multiple ascending doses (MAD) of NNC0174-1213 will be administered to cohorts 1-5. |
| Part B: Cagrilintide (MDA) | EXPERIMENTAL | Part B: Multiple ascending doses (MAD) of Cagrilintide MDA will be administered to cohorts 1-5. |
| Part B: Placebo | EXPERIMENTAL | Part B: Multiple ascending doses (MAD) of placebo will be administered to cohorts 1-5. |
| Name | Type | Description |
|---|---|---|
| NNC0174-1213 A | DRUG | Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts. |
| Cagrilintide B | DRUG | Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts. |
| Placebo A (NNC0174 1213 A) | DRUG | Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts. |
Inclusion Criteria: * Male. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigat...
Top 20 of 32 competitors
NNC0174-1213 A is an investigational small molecule being developed for the treatment of obesity. It is being studied in people with overweight or obesity. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC0174-1213 A is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's effects in people with overweight or obesity.
NNC0174-1213 A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The drug is being studied for its effects in people with overweight or obesity, and its development is still in the early stages.
NNC0174-1213 A has been studied in one clinical trial with the identifier NCT06719011. This Phase 1 trial, titled 'A Study on How NNC0174-1213 Works in People With Overweight or Obesity,' was completed and enrolled 178 male participants aged 18 years and older in the United States.
No alternative names for NNC0174-1213 A have been disclosed. The drug is identified by its code name NNC0174-1213 A and is being developed by Novo Nordisk A/S. It is a small molecule intended for the treatment of obesity.